Skip to content
OpenCapital
Get started

Thermo Fisher Scientific TMO Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$32.31M+20.5%
Quanterix Corporation logo
Quanterix CorporationQTRX
——
908 Devices logo
908 DevicesMASS
——
IR
Ingersoll RandIR
——

Other financials

Income statement

See full
Revenue$11.0B+6.2%
Operating income$1.9B+8.6%
Net income$1.7B+9.6%
EPS (diluted)$4.43+11.3%

Balance sheet

See full
Cash & equivalents$3.3B-21.4%
Total debt$43.2B+16.6%
Total equity$51.9B+5.2%
Total assets$113.28B+14.4%

Cash flow

See full
Operating cash flow$1.2B+64.9%
CapEx$376.0M+3.9%
Free cash flow$816.0M+126%

Valuation

See full
Market cap$186.32B+25.0%
Enterprise value$226.2B+24.4%
P/E27.2×+4.6×
P/S4.3×-0.8×

Profitability

See full
Gross margin58.3%—
Operating margin17.2%+0.8pp
Net margin15.2%+1.0pp
FCF margin15.7%-2.1pp

Returns & leverage

See full
Return on equity13.5%-0.2pp
Debt / equity0.8×+0.1×
Current ratio1.5×-0.2×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Thermo Fisher Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Thermo Fisher Scientific's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Thermo Fisher Scientific's deferred revenue, net of current portion?
Thermo Fisher Scientific (TMO) reported deferred revenue, net of current portion of $1.03B in Q1 2026.
How has Thermo Fisher Scientific's deferred revenue, net of current portion changed year-over-year?
Thermo Fisher Scientific's deferred revenue, net of current portion decreased by 8.3% year-over-year, from $1.13B to $1.03B.
What is the long-term trend for Thermo Fisher Scientific's deferred revenue, net of current portion?
Over 5 years (2020 to 2025), Thermo Fisher Scientific's deferred revenue, net of current portion has grown at a 9.2% compound annual growth rate (CAGR), from $763M to $1.18B.